Higher Levels of hematocrit and hemoglobin - What is "High", What are the Risks? Testosterone Impact, etc

LukeMV · October 28, 2026, 7:28pm

I think one day, we will all realize that hematocrit and hemoglobin are markers and not causes of cardiovascular events. It could take ten more years before everyone comes to that consensus but it’s already beginning.

John_Hemming · October 28, 2026, 7:46pm

If HCT is too high that can be an issue.

LukeMV · October 28, 2026, 7:49pm

That is debatable

John_Hemming · October 28, 2026, 8:06pm

Gemini:Three of the most significant references demonstrating the clinical risks and thrombotic complications associated with elevated hematocrit are detailed below:

The CYTO-PV Collaborative Group Trial: This landmark multi-center randomized trial established the gold standard target for hematocrit control. It demonstrated that patients managed to a hematocrit target of 45% or higher experienced a nearly fourfold higher rate of cardiovascular mortality and major thrombotic complications (including stroke, myocardial infarction, and pulmonary embolism) compared to those strictly maintained below 45% (Marchioli et al., 2013).
The Tromsø Study: Examining the effects of hemoconcentration in the broader population rather than exclusively in bone marrow disorders, this prospective population-based cohort demonstrated that elevated hematocrit is an independent risk factor for venous thromboembolism (VTE) due to increased blood viscosity and impaired venous hemodynamics (Braekkan et al., 2009).
Current Evidence-Based Management Guidelines: Comprehensive practice updates synthesize decades of hematologic research on absolute erythrocytosis, emphasizing strict maintenance of hematocrit below 45% via therapeutic phlebotomy and cytoreduction to prevent major arterial and venous vascular occlusions (Tefferi & Barbui, 2023).
References
Braekkan, S. K., Mathiesen, E. B., Njolstad, I., Wilsgaard, T., & Hansen, J.-B. (2009). Hematocrit and risk of venous thromboembolism in a general population. The Tromso study. Haematologica, 95, 270-275. Hematocrit and risk of venous thromboembolism in a general population. The Tromsø study | Haematologica
Cited by: 279
Marchioli, R., Finazzi, G., Specchia, G., et al. (2013). Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. New England Journal of Medicine, 368, 22-33. https://doi.org/10.1056/nejmoa1208500
Cited by: 1199
Tefferi, A., & Barbui, T. (2023). Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 98, 1465-1487. https://doi.org/10.1002/ajh.27002
Cited by: 369

LukeMV · October 28, 2026, 8:27pm

@John_Hemming The first and third study you posted are in people with polycythemia vera and not the general population

The second was general population but only proves association and not a cause.

People at very high altitudes and on testosterone replacement are not at increased risk and they have much higher hematocrits than regular folks at sea level. Then people on SGLT2 have lower risk despite many with higher hematocrit.

A new drug was just approved called Rusfertide for polycythemia vera patients that decreases hematocrit. I’m very curious if that will translate to better outcomes and lower risk of cardiovascular events/PVT

John_Hemming · October 28, 2026, 8:34pm

ChatGPT: Worked for 2m 29s

I found six relevant published patient reports. Raised HCT is described as erythrocytosis or secondary polycythaemia. For reference, HCT 0.55 means 55%.

Published report Patient and testosterone treatment HCT reported Clinical course

Cervi and Balitsky, 2017 — Testosterone use causing erythrocytosis 60-year-old man using topical testosterone. His pretreatment testosterone was normal, so the indication for replacement was questionable. 46% to 58% Presented with sudden headache, facial flushing and blood pressure of 190/112. Stopping testosterone and performing venesection brought HCT down to 45%.
Switch to restoration therapy…, 2017 66-year-old man with hypogonadotropic hypogonadism, using testosterone gel 40 mg/day. 57.3% Testosterone was stopped and haemoglobin normalised. Restarting gel at only 10 mg/day caused recurrent erythrocytosis, with HCT 52.2%. He subsequently switched to off-label clomiphene. His testosterone at the initial high HCT was 15.22 nmol/L, showing that a markedly elevated testosterone concentration was not necessary.
Francisco et al., 2019 — Clomiphene for hypogonadism complicated by polycythemia 45-year-old man receiving intramuscular testosterone every two weeks; also had obesity and sleep apnoea treated with CPAP. 55% Had previously required venesection. After stopping testosterone, HCT fell to 49.5% at six weeks, then 46.7% at a later visit. No recurrent polycythaemia was reported after switching to clomiphene.
Engel and Sarvaideo, 2023 — Erythrocytosis Associated With Oral Testosterone Replacement 55-year-old man with secondary hypogonadism, initially receiving injections, then oral testosterone undecanoate. Baseline 43.6%; injections 52.7%; oral treatment 55.1% Blood donation and dose reduction were followed by another rise to 53.7%, despite testosterone measuring 522 ng/dL. Stopping treatment reduced HCT to 45.8–48.9%. No smoking or sleep apnoea was reported. Conference case abstract.
Al-Thunaibat et al., 2025 — Testosterone-induced Polycythemia Leading To Life-threatening Venous Thromboembolism 45-year-old man with primary hypogonadism, on TRT for over seven years; also had sleep apnoea treated with CPAP. 55% Developed extensive bilateral pulmonary emboli with right-heart strain and a leg DVT. He had known polycythaemia and had missed scheduled venesections. Treated with catheter-directed thrombolysis and anticoagulation; TRT was discontinued. Conference case abstract.
El Hadi et al., 2026 — Diagnostic challenge of pulmonary embolism during testosterone replacement therapy 50-year-old man receiving testosterone enanthate who had independently increased injection frequency. 53.4% Persistent fatigue and reduced exercise tolerance led to detection of bilateral pulmonary emboli. Testosterone was 52 nmol/L. TRT was stopped, anticoagulation started and venesection arranged. Four months later, HCT was 49% and fatigue had resolved.

The 66-year-old gel case provides particularly useful evidence linking testosterone to the HCT rise, because erythrocytosis recurred when treatment was restarted at a lower dose. The clotting cases document serious events occurring alongside elevated HCT, but cannot establish that HCT alone caused them.

For context, Endocrine Society guidance recommends withholding testosterone when HCT exceeds 54%, investigating hypoxia and sleep apnoea, and restarting at a reduced dose after HCT falls. That is an intervention threshold; the precise HCT at which clotting risk increases remains uncertain.

LukeMV · October 28, 2026, 9:29pm

A few case studies looking to conveniently blame hematocrit because they can’t let go of this idea that it’s dangerous is not that compelling to me. High hematocrit is extremely common in the populations I mentioned. Let’s see those people’s echocardiograms.

Davin8r · October 28, 2026, 11:05pm

Andrew Winge did an interesting video on the hematocrit issue a few weeks ago that I enjoyed. It made me feel slightly better about borderline-high hematocrit from TRT as long as other risk factors are controlled, but my other problem is that the erythrocytosis also drains my ferritin into the teens, causing iron deficiency.

Since rusfertide solves both the hematocrit and the ferritin issue at the same time with just a simple once weekly subcutaneous injection and apparently very little risk of side effects, it’s a very appealing option. It’s crazy to me that nobody in the gray market peptide world seems to even be aware of its existence.

RapAdmin · October 28, 2026, 11:27pm

I. Executive Summary

This clinical peer review evaluates the presentation delivered by an emergency physician and hormone therapy prescriber on the YouTube channel Man Medicine, titled “How Dangerous Is A High Hematocrit?”. The video serves as an adversarial critique of an alarmist clip featuring exercise physiologist Dr. Ben House on Dr. Andy Galpin’s podcast,wherein House asserted that a hematocrit exceeding 52% or 54% represents an acute, life-threatening emergency requiring middle-of-the-night calisthenics (air squats) to avert fatal thromboembolic events, alongside universal pre-exercise electrocardiograms and cardiac stress testing.

The primary thesis posits that clinical guidelines establishing arbitrary thresholds—specifically the Endocrine Society’s 54% cutoff for testosterone replacement therapy (TRT) cessation—represent Level E expert consensus rather than empirically verified hemodynamic inflection points. Hemorheologic data demonstrate that whole-blood viscosity increases nonlinearly with hematocrit. However, human microvasculature leverages non-Newtonian, pseudoplastic shear-thinning behavior via the Fåhræus–Lindqvist effect, significantly buffering peripheral vascular resistance down to capillary diameters below 300 micrometers.

Furthermore, epidemiological and clinical data from populations with extreme secondary erythrocytosis (e.g., high-altitude Andean natives and cyanotic congenital heart disease cohorts such as Eisenmenger syndrome) demonstrate that isolated red blood cell mass expansion does not intrinsically trigger unprovoked thrombosis absent concurrent endothelial trauma, profound stasis, or iron deficiency-induced erythrocyte microcytosis. The speaker systematically deconstructs common clinical folklore surrounding early-1990s European cyclist fatalities attributed to recombinant erythropoietin (EPO), identifying post-viral myocarditis, coronary atherosclerosis, and hypertrophic cardiomyopathy as primary etiologies rather than isolated hyperviscosity. Finally, the analysis cautions against screening low-pretest-probability asymptomatic individuals with exercise stress tests, citing Bayesian probability and guideline consensus from the American College of Cardiology and American Heart Association regarding excessive false-positive cascades. The clinician concludes that while hematocrit warrants longitudinal surveillance and therapeutic modification primarily for medico-legal risk management and secondary polycythemia stewardship, an asymptomatic hematocrit of 52% to 55% does not constitute an acute thrombotic emergency.

II. Insight Bullets

Clinical practice guidelines represent consensus frameworks intended to minimize error among non-specialists rather than rigid physiological laws.
The 54% hematocrit suspension threshold established in the Endocrine Society Clinical Practice Guidelines is graded as “very low-quality evidence” (GRADE system) based strictly on expert consensus.
The Endocrine Society explicitly acknowledges within its text that the exact hematocrit threshold at which neuro-occlusive or cardiovascular risk escalates remains empirically undetermined.
Randomized controlled trials evaluating testosterone therapy demonstrate a very low incidence of neuro-occlusive events among hypogonadal men developing erythrocytosis.
A retrospective database study by Ory et al. (2022) in The Journal of Urology identified a 1.28% absolute risk difference in adverse events above versus below an arbitrarily designated 52% hematocrit cutoff.
The cohort analyzed by Ory et al. exhibited substantial baseline cardiometabolic confounding, including 54% hypertension, 34% obesity, and 25% sleep apnea lacking documented continuous positive airway pressure (CPAP) compliance.
A subsequent review co-authored by White, Petrella, and Ory (2022) acknowledged that evidence demonstrating clinical harm from secondary erythrocytosis is scarce and existing cutoff values are arbitrary.
Retrospective claims analyses in testosterone replacement therapy frequently fail to control for patient compliance,formulation-specific pharmacokinetics, or serum testosterone concentrations.
Whole blood operates as a non-Newtonian, pseudoplastic fluid whose apparent viscosity decreases under increasing shear rates and flow velocities.
Escalating hematocrit from 50% to 54% yields a modest 7% to 8% elevation in apparent whole-blood viscosity under physiological shear conditions.
Microvascular blood flow in vessels under 300 micrometers is regulated by the Fåhræus–Lindqvist effect, where erythrocytes migrate axially, creating a cell-free marginal plasma lubricating layer.
As demonstrated by Gordeuk, Key, and Prchal (2019) in Haematologica , isolated secondary erythrocytosis is biologically distinct from primary polycythemia vera.
Polycythemia vera carries intrinsic thrombotic risk driven by clonal JAK2 mutations, leukocyte activation, and platelet hypersensitivity, which persist even when hematocrit is corrected below 45%.
In the Framingham Heart Study, the association between elevated hematocrit and stroke risk disappeared in multivariate models after controlling for cigarette smoking.
British regional cohort analyses identified no correlation between hematocrits exceeding 51% and stroke incidence among normotensive men, isolating the primary risk to concurrent hypertension.
Patients with Eisenmenger syndrome maintain lifetime baseline hematocrits of 55% to 65% or higher without exhibiting proportional rates of primary thrombotic occlusion.
Professional guidelines from the Adult Congenital Heart Association and pediatric cardiology consortia strictly contraindicate routine phlebotomy in stable Eisenmenger syndrome due to microcytic stroke risk.
Repeated phlebotomies without iron repletion deplete ferritin, generating iron-deficient microcytic erythrocytes with diminished cellular deformability that paradoxically elevate hyperviscosity and stroke risk.
Hyperviscosity syndrome is predominantly an oncological manifestation of hypergammaglobulinemia (e.g.,Waldenström macroglobulinemia, multiple myeloma) or extreme leukemic blast crises exceeding 100,000 cells per microliter.
In cyanotic congenital heart disease, pulmonary in situ thrombosis occurs secondary to severe pulmonary endothelial disruption and luminal stasis (Virchow’s triad), not elevated erythrocyte mass alone.
Historical claims attributing the sudden deaths of 18 to 20 European cyclists in the late 1980s and early 1990s directly to recombinant erythropoietin (EPO) are largely uncorroborated by autopsy toxicology.
As documented by López (2011) in Sport in History , verified athlete fatalities from that era showed mortality rates comparable to general athletic sudden cardiac death baselines.
Autopsy data from competitive cyclists who died during that timeframe predominantly revealed post-viral lymphocytic myocarditis, severe coronary artery disease, and undiagnosed arrhythmogenic congenital anomalies.
The widely repeated narrative that endurance cyclists were forced to perform nocturnal air squats to thin sludgy blood lacks both empirical documentation and physiological validity.
Nocturnal calisthenics induce diaphoresis, peripheral dehydration, and hemoconcentration, which acutely exacerbate rheologic viscosity and elevate catecholamine-driven plaque rupture risks.
Vigorous muscular contraction in the setting of suspected or incipient deep venous thrombosis increases mechanical shear stresses that promote proximal clot detachment and fatal pulmonary embolism.
Concentric left ventricular hypertrophy (LVH) in elite endurance and strength athletes frequently represents physiological athletic remodeling with preserved diastolic relaxation and normal ejection fraction.
Pathological LVH results primarily from sustained hydraulic afterload excess due to decades of untreated systemic arterial hypertension, rather than isolated erythrocyte mass expansion.
Preclinical transgenic murine models with chronic erythropoietin overexpression yielding hematocrits of 85% demonstrated an absence of systemic microvascular thrombosis upon histological necropsy (Shibata et al., 2003).
Universal graded exercise stress testing in asymptomatic, low-risk men initiating fitness regimens or hormone therapy generates high rates of false-positive outcomes due to low pre-test disease prevalence.
Nuclear SPECT myocardial perfusion imaging demonstrates an average sensitivity of roughly 82% and specificity of 74%, leaving significant margins for false-positive diagnostic cascades.
The 2023 AHA/ACC Guidelines for Chronic Coronary Disease explicitly restrict stress testing to symptomatic patients or individuals with high-risk clinical markers such as coronary artery calcium (CAC) scores over 1000.
Routine screening electrocardiography solely to detect asymptomatic atrial fibrillation in healthy young adults lacks clinical utility and is not endorsed by major cardiovascular guideline bodies.
Prescribers routinely manage secondary erythrocytosis via dose titrations, formulation modifications, or conservative phlebotomy primarily to insulate against tort liability rather than acute hemodynamic collapse.

III. Adversarial Claims & Evidence Table

Claim from Video	Speaker’s Evidence	Scientific Reality (Current Data)	Evidence Grade (A-E)	Verdict
1. Hematocrit >52%–54% warrants immediate TRT cessation and urgent intervention to prevent acute mortality.	Dr. Ben House citing standard clinical guidance and acute cardiac/stroke mortality risk.	The landmark TRAVERSE Trial (Lincoff et al., 2023) randomized 5,246 hypogonadal men on TRT and confirmed no increase in primary Major Adverse Cardiovascular Events (MACE). The Endocrine Society 54% threshold is based on Level E expert opinion; real-world data link adverse events to baseline metabolic comorbidities rather than an isolated cutoff.	Level B(Human RCT)	Unsupported(Acute Risk Overstated)
2. Hematocrit exceeding 52% increases 1-year MACE and VTE risk in men receiving TRT.	Citation of Ory et al. (2022) in The Journal of Urology.	Retrospective observational design with an arbitrarily assigned 52% cutoff. Cohort possessed severe baseline confounding (54% hypertension, 34% obesity, 25% sleep apnea, 23% diabetes). Author’s subsequent review (White et al., 2022) conceded evidence of clinical harm is scarce and thresholds remain arbitrary.	Level C(Observational Cohort)	Speculative(Conflicted by Confounders)
3. Whole-blood viscosity becomes catastrophic (“ketchup/motor oil”) at hematocrits between 50% and 59%.	Whole-blood rheology curves and relative apparent viscosity metrics.	In vitro and human rheology confirms relative apparent viscosity increases moderately from ~2.26 to ~2.72 between 50% and 59% Hct. In microvessels (<300 μm), the non-Newtonian Fåhræus–Lindqvist effect attenuates resistance via axial RBC streaming and marginal plasma flow (Secomb, 2017).	Level C(Physiological / Cohort)	Plausible(Mechanistically Real, Clinically Exaggerated)
4. Isolated secondary erythrocytosis intrinsically induces systemic thrombosis.	Comparison of primary polycythemia vera (PV) to secondary erythrocytosis.	Systematic reviews confirm thrombotic diathesis in PV is driven by JAK2 V617F clonal mutations, leukocyte activation, and platelet hyperreactivity, not erythrocyte mass alone (Gordeuk et al., 2019). Secondary erythrocytosis in high-altitude dwellers and congenital heart disease lacks matched thrombosis rates absent endothelial injury.	Level A(Systematic Review)	Unsupported
5. Therapeutic phlebotomy is universally indicated for high hematocrit regardless of etiology.	Endocrine Society clinical guidelines recommending phlebotomy or cessation.	Aggressive phlebotomy in secondary erythrocytosis (e.g., Eisenmenger syndrome) precipitates iatrogenic iron deficiency. Microcytic, hypochromic red cells have rigid membranes with reduced deformability, paradoxically accelerating microvascular occlusion and stroke (Broberg et al., 2007).	Level C(Human Cohort / Guidelines)	Safety Warning
6. Professional cyclists in the 1980s–1990s died from EPO-induced hyperviscosity and had to perform nocturnal air squats to survive.	Sports folklore surrounding European cyclist fatalities and EPO abuse.	Histopathological autopsy series of competitive cyclist deaths demonstrated acute viral myocarditis, severe coronary atherosclerosis, arrhythmogenic right ventricular cardiomyopathy, and WPW syndrome (López, 2011). Confirmed EPO-positive cases had hematocrits near ~50%–51%, not >60%.	Level C(Autopsy Case Series)	Unsupported(Folklore)
7. Nocturnal exercise / air squats mechanically protect against hyperviscosity-induced death.	Claim that physical movement restores capillary perfusion during nocturnal bradycardia.	Nocturnal vigorous exercise elevates sympathetic tone, increases blood pressure, induces sweat-mediated plasma volume loss (exacerbating hemoconcentration), and introduces shear stress capable of dislodging occult venous thrombi into the pulmonary circulation.	Level E(Expert Physiological Consensus)	Safety Warning
8. Pre-exercise graded stress testing and baseline ECGs are mandatory prior to starting TRT or resistance training.	Anecdotal recommendation from fitness industry coaching protocols.	According to the 2023 ACC/AHA Chronic Coronary Disease Guidelines, routine screening of asymptomatic individuals is contraindicated due to low Bayesian pre-test probability, generating high false-positive rates that trigger unnecessary invasive coronary angiographies.	Level A(Clinical Practice Guidelines)	Unsupported

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

Domain	Clinical Action	Dosing / Target	Primary Endpoint
Cardiovascular Screening	Restrict graded exercise stress testing exclusively to individuals meeting high-risk criteria under the 2023 ACC/AHA Guidelines.	Indicated only if: Coronary Artery Calcium (CAC) score > 1000, functional capacity < 4 METs with clinical symptoms, new-onset pathological arrhythmia, or known ischemic coronary artery disease.	Prevention of false-positive testing cascades and avoidance of unindicated invasive diagnostic angiographies.
Hormone Formulation Optimization	Transition from high-peak intramuscular testosterone esters to daily transdermal or micro-dosed subcutaneous regimens upon observing secondary erythrocytosis.	Titrate transdermal gel (50–100 mg daily) or divided subcutaneous testosterone cypionate (20–30 mg three times weekly) to maintain mid-normal steady-state levels without supraphysiological transient spikes (Kohn et al., 2022).	Mitigation of excessive renal erythropoietin (EPO) pulses and attenuation of hepatic hepcidin suppression.
Therapeutic Phlebotomy Criteria	Restrict therapeutic venesection strictly to confirmed symptomatic hyperviscosity or verified primary myeloproliferative neoplasms (polycythemia vera).	Maintain hematocrit < 45% in Polycythemia Vera (Marchioli et al., CYTO-PV, NEJM 2013); in TRT-induced secondary erythrocytosis, limit phlebotomy (450–500 mL) to persistent Hct > 54% with coexisting intractable neuro-viscosity symptoms.	Reduction of verified thrombotic event rates in primary clonal disease while preventing iatrogenic iron starvation in secondary erythrocytosis.

Experimental Tier (Level C/D Evidence - High Safety Margin)

Plasma Volume Maintenance: Target a daily baseline fluid intake of 35–45 mL/kg/day of water supplemented with 500–1000 mg sodium chloride during intense training bouts. This supports intravasal hydrostatic volume,counteracts acute hemoconcentration, and preserves physiological shear rates in peripheral microvessels. Monitor via first-morning urine specific gravity (target < 1.015).
Obstructive Sleep Apnea Management: Conduct formal home sleep apnea testing (HSAT) for any TRT patient exhibiting progressive erythrocytosis. Initiate automated positive airway pressure (APAP ) with titration to maintain an Apnea-Hypopnea Index (AHI ) < 5 events/hr. Nocturnal intermittent hypoxemia acts synergistically with exogenous androgens to drive renal hypoxia-inducible factor (HIF-2α) expression; CPAP adherence directly blunts aberrant EPO upregulation.
Cellular Deformability & Iron Optimization: Measure serum ferritin, serum iron, and total iron-binding capacity (TIBC) prior to ordering therapeutic phlebotomies. Maintain serum ferritin > 50 ng/mL and transferrin saturation > 20% . If ferritin falls below 30 ng/mL, withhold phlebotomy and administer low-dose oral iron bisglycinate (25–50 mg elemental iron every other day ) to avert microcytic erythrocyte rigidity.
Low-Dose Antiplatelet Prophylaxis: In individuals with persistent hematocrit between 52% and 54% who possess concurrent subclinical cardiovascular risk factors (e.g., coronary calcium > 100, controlled hypertension),administer enteric-coated aspirin at 81 mg daily . This offsets thromboxane A2-mediated platelet reactivity without disrupting hemodynamic autoregulation.

Red Flag Zone (Debunked, High-Risk, or Contraindicated)

Nocturnal Calisthenics (“Air Squats”) for High Hematocrit: Performing vigorous physical exercise in the middle of the night to counteract presumed hyperviscosity is strictly contraindicated. Calisthenics accelerate peripheral diaphoresis, leading to acute hemoconcentration and increased blood viscosity. Furthermore, the transient surge in systemic arterial pressure and peripheral venous mechanical compression significantly elevates the risk of dislodging an occult deep vein thrombosis into a fatal pulmonary embolism.

Routine Depletive Phlebotomy in Asymptomatic Secondary Erythrocytosis: Subjecting patients on TRT with an asymptomatic hematocrit of 52% to 55% to frequent, unmonitored venesection without assessing iron stores is clinically hazardous. Recurrent phlebotomy induces severe microcytic iron deficiency anemia superimposed on erythrocytosis. Rigid, iron-depleted microcytes substantially impair capillary deformability, paradoxically increasing peripheral vascular resistance and elevating stroke incidence.

Universal Pre-Exercise Cardiac Stress Testing in Asymptomatic Low-Risk Adults: Mandating graded exercise treadmill testing or myocardial SPECT scans for asymptomatic individuals initiating exercise or testosterone replacement is medically unwarranted. Given low disease prevalence in this cohort, Bayesian probability guarantees a high proportion of false-positive findings, exposing patients to unwarranted procedural risks, cardiac catheterization complications, and psychogenic distress.

Produced by Gemini 2.5 Pro

RapAdmin · October 28, 2026, 11:39pm

And the video they were critical of:

I. Executive Summary

This clinical and endocrinological audit evaluates the long-form scientific discussion between Dr. Andy Galpin and Dr.Ben House on testosterone physiology, diagnostic testing inaccuracies, muscular hypertrophy adaptations, and testosterone replacement therapy (TRT), presented on the Andy Galpin Channel. The primary thesis asserts that circulating total testosterone concentrations within the physiological eugonadal range (approximately 264 to 1,000 ng/dL) demonstrate zero predictive validity or correlative relationship with resistance exercise-induced muscular hypertrophy in healthy men. Furthermore, the ubiquitous clinical narrative of an obligatory 1% to 2% annual age-related decline in testosterone (“andropause”) is deconstructed as an epidemiological artifact driven by progressive adiposity, visceral ectopic fat accumulation, chronic sleep deprivation, and cardiometabolic multimorbidity, rather than chronological aging alone.

House and Galpin emphasize that diagnostic endocrinology panels are confounded by severe analytical and biological noise. Diurnal circadian rhythms—marked by slow-wave and REM sleep-dependent secretory bursts yielding morning peaks, followed by late-afternoon nadirs 30% to 40% lower—compound with intra-assay coefficients of variation (12% to 15% for immunoassays) to produce aggregate variability exceeding 25% to 30%. Consequently, isolated blood draws frequently lead to false-positive diagnoses of hypogonadism. They advocate for strict standardized protocols: repeat fasting 7:00 AM to 8:00 AM draws, liquid chromatography–tandem mass spectrometry (LC-MS/MS), and equilibrium dialysis for free testosterone, warning that calculated indices based on the Vermeulen formula misrepresent bioavailable hormone dynamics due to fluid shifts and fluctuating sex hormone-binding globulin (SHBG) levels.

Critically, the authors highlight that low testosterone functions primarily as a sensitive physiological “canary in the coal mine,” signaling systemic energy deficits, central leptin resistance, hepatic steatosis, or varicocele-induced testicular venous hypertension, rather than primary testicular failure. They vigorously critique direct-to-consumer TRT clinics that initiate exogenous androgens without investigating root etiologies. Supraphysiological “TRT-plus” regimens suppress the hypothalamic-pituitary-gonadal (HPG) axis, induce testicular atrophy, elevate secondary hematocrit, and carry documented cardiovascular safety liabilities in non-hypogonadal populations, whereas lifestyle interventions—targeted caloric refeeds, weight loss in obesity, and surgical varicocelectomy—reliably restore endogenous endocrine homeostasis.

II. Insight Bullets

Total testosterone concentrations within the physiological eugonadal range (300 to 1,000 ng/dL) show no statistically significant correlation with resistance training-induced skeletal muscle hypertrophy, as documented across multiple human trials (Mobley et al., 2018; Haun et al., 2018).
Endogenous testosterone suppression to near-castrate levels via GnRH agonists blunts, but does not entirely abolish, muscular hypertrophy and isometric strength adaptations during resistance training (Kvorning et al., 2006).
Overweight young men undergoing heavy resistance circuits in a severe 40% caloric deficit experienced an 80% collapse in circulating testosterone while simultaneously gaining lean body mass and losing substantial adipose tissue (Longland et al., 2016).
Ketogenic and low-carbohydrate, high-fat diets can elevate resting total testosterone by approximately 20%, yet fail to confer additive benefits in muscular strength or hypertrophic gains (Whittaker & Harris, 2022).
Pre-analytical diurnal biological variability causes serum testosterone to decline by 30% to 40% from morning peak to late afternoon nadir in healthy young adult males (Diver et al., 2003).
The harmonized normal reference range for circulating total testosterone in healthy, non-obese young men established by the CDC and the Endocrine Society is 264 to 916 ng/dL (Bhasin et al., 2017).
Diagnostic guidelines from professional medical bodies mandate at least two separate, confirmed morning fasting blood draws combined with clinical symptomatology prior to diagnosing hypogonadism (Bhasin et al., 2018).
Standard automated immunoassay testing for free and total testosterone carries intra-assay error rates of 12% to 15%, rendering mass spectrometry and equilibrium dialysis essential for precise evaluation.
Calculated free testosterone using the Vermeulen equation relies heavily on albumin and SHBG concentrations,which are distorted by acute plasma volume shifts and hydration changes.
Approximately 45% to 50% of circulating testosterone is bound to albumin and remains readily dissociable within peripheral microvascular capillary beds, refuting the concept that only the 2% free fraction is bioavailable.
Hepatic steatosis and visceral adiposity suppress hepatic synthesis of sex hormone-binding globulin (SHBG),driving down measured total testosterone in metabolically compromised cohorts.
Serum SHBG reference ranges are established on metabolically unhealthy populations, causing healthy athletic cohorts to falsely appear on the high end of normal.
Large-scale individual participant meta-analyses demonstrate that circulating testosterone does not decline with chronological age prior to 70 years in men who remain free of metabolic syndrome, diabetes, and obesity (Marriott et al., 2023).
Longitudinal cohort models tracking validated normative datasets across the human lifespan confirm that testosterone variance widens after age 70 due to chronic disease prevalence rather than primary aging (Kelsey et al., 2014).
In the general population, male obesity accounts for the vast majority of secondary hypogonadism diagnoses, and moderate weight loss or bariatric surgery reliably increases total testosterone by over 200 ng/dL.
Severe acute energy deficits and operational stress environments, such as military special forces selection, suppress serum testosterone into castrate ranges via central hypothalamic downregulation (Friedl et al., 2000).
Restricting nocturnal sleep duration to 5 hours per night for one week induces a 10% to 15% reduction in daytime testosterone concentrations in healthy young men (Leproult & Van Cauter, 2011).
Dietary refeeding with carbohydrates rapidly reduces elevated SHBG and restores circulating testosterone after prolonged hypocaloric dieting.
Clinical varicocele occurs in a high percentage of heavy resistance lifters due to chronic intra-abdominal pressure generation, and surgical varicocelectomy reliably elevates serum testosterone by 100 to 150 ng/dL (Gomes et al., 2021).
Exogenous testosterone administration completely abolishes endogenous LH and FSH secretion, resulting in testicular atrophy and severe suppression of spermatogenesis within weeks.
Abrupt cessation of exogenous testosterone without medical gonadotropin management exposes patients to severe hypogonadal withdrawal syndromes, psychiatric disturbances, and depressive states.
Supra-physiological testosterone dosing creates a linear, dose-dependent accrual of fat-free mass and muscle volume that breaks the physiological ceiling observed in eugonadal states (Bhasin et al., 1996).
The landmark TRAVERSE trial established cardiovascular safety exclusively for transdermal testosterone replacing levels to mid-normal ranges in diagnosed hypogonadal men, not for supra-physiological regimens (Lincoff et al., 2023).
Cohort analyses indicate that administering testosterone therapy to men without clinical hypogonadism is associated with a 51% increase in major adverse cardiovascular events (Layton et al., 2014).
Preserving physiological estradiol concentrations is critical in men on androgen therapy, as complete estrogen suppression with aromatase inhibitors precipitates severe sexual dysfunction, loss of bone mineral density, and vasomotor symptoms (Finkelstein et al., 2013).
Quantifying soft tissue adaptations and muscle volumes in elite athletic cohorts requires advanced MRI imaging technologies, such as those provided by Springbok Analytics.
Secondary erythrocytosis on TRT results from renal erythropoietin stimulation and hepatic hepcidin suppression,necessitating regular complete blood count surveillance.
An isolated hematocrit of 52% to 54% represents a chronic microvascular viscosity parameter rather than an acute nocturnal thrombotic emergency requiring emergency calisthenics (White et al., 2022).
Universal graded exercise stress testing in asymptomatic, low-risk men initiating fitness routines generates excessive false-positive outcomes that trigger unnecessary invasive coronary angiographies (ACC/AHA Guidelines, 2023).
The modern secular decline in male population-level testosterone is driven predominantly by rising obesity rates,physical inactivity, and metabolic disease rather than intrinsic testicular degeneration (Santi et al., 2025).

III. Adversarial Claims & Evidence Table

Claim from Video	Speaker’s Evidence	Scientific Reality (Current Data)	Evidence Grade (A-E)	Verdict
1. Eugonadal testosterone concentrations (300–1,000 ng/dL) do not correlate with muscle hypertrophy gains from resistance training.	Null findings across multiple resistance training cohorts (Haun et al., 2018; Mobley et al., 2018).	Confirmed across multiple controlled trials. Intra-muscular androgen receptor content, ribosome biogenesis, and mechanical tension dictate myofibrillar protein synthesis within eugonadal limits, not serum hormone deltas.	Level B(Human RCT / Interventions)	Strong Support
2. Severe energy restriction with heavy resistance training causes an acute testosterone collapse while supporting fat loss and muscle gain.	Citation of Longland et al. (2016) (40% caloric deficit, 2.4 g/kg protein, 6 days/wk training).	RCT confirmed 80% collapse in serum testosterone due to central energy depletion, yet the high-protein resistance training group gained 1.2 kg lean mass via 4-compartment body modeling.	Level B(Human RCT)	Strong Support
3. Endogenous testosterone suppression to castrate levels blunts but does not stop muscle growth.	Citation of goserelin trials (Kvorning et al., 2006).	RCT demonstrated that chemically castrated young men (testosterone <30 ng/dL) still achieved significant leg lean mass increases, though attenuated compared to placebo (~43% reduction in hypertrophy).	Level B(Human RCT)	Strong Support
4. Testosterone inevitably declines by 1% to 2% annually in healthy aging men (“andropause”).	Conventional clinical narrative refuted by recent longitudinal epidemiological cohorts.	Individual participant meta-analysis of over 25,000 men confirmed no age-associated decline prior to age 70 after adjusting for obesity, diabetes, and smoking status (Marriott et al., 2023).	Level A(Meta-analysis / Cohort)	Unsupported(Debunked Narrative)
5. Obesity is the primary driver of secondary hypogonadism via hepatic steatosis and leptin resistance.	Mechanistic link between liver fat, low SHBG, and hypothalamic dampening.	Human clinical data confirm visceral adiposity downregulates hepatic SHBG transcription and induces hypothalamic leptin resistance, suppressing Kisspeptin and GnRH release; weight loss reverses this deficit (Marriott et al., 2023).	Level A(Meta-analysis / Clinical)	Strong Support
6. Routine automated immunoassay testing of free/total testosterone carries excessive error rates (15%–30%).	Analytical chemistry standards comparing immunoassays to LC-MS/MS and equilibrium dialysis.	Endocrine Society reference standards confirm direct immunoassays suffer significant cross-reactivity and inaccuracy at low/borderline ranges, mandating LC-MS/MS and equilibrium dialysis (Bhasin et al., 2018).	Level A(Clinical Practice Guidelines)	Strong Support
7. Hematocrit >52%–54% on TRT poses an acute “wake up dead” emergency requiring middle-of-the-night calisthenics.	Speaker’s initial reaction video clip criticizing endurance doping folklore.	Disproven by clinical trials and microvascular rheology. Isolated secondary erythrocytosis increases blood viscosity moderately, buffered by the Fåhræus–Lindqvist effect; acute exercise dehydrates plasma and elevates PE risk (White et al., 2022).	Level C(Physiological Review / Cohort)	Safety Warning
8. Clinical varicocele is common in heavy lifters and surgical repair raises testosterone by 100–150 ng/dL.	Urological data in athletes performing frequent Valsalva maneuvers.	Meta-analyses confirm surgical varicocelectomy significantly increases serum testosterone (mean improvement 100–140 ng/dL) by relieving scrotal hyperthermia and venous stasis (Gomes et al., 2021).	Level A(Systematic Review / Meta-analysis)	Strong Support
9. TRT prescribed to men without true pathological hypogonadism increases major adverse cardiovascular events (MACE).	Retrospective pharmacoepidemiology citing a 51% increased risk.	Large observational database studies confirm that prescribing exogenous testosterone to eugonadal men or without verified hypogonadism increases MACE risk (Layton et al., 2014). The TRAVERSE trial confirmed safety only in diagnosed hypogonadism (Lincoff et al., 2023).	Level C(Observational Cohort)	Plausible(Risk in Eugonadal Misuse)
10. Aggressive aromatase inhibition (low estradiol) impairs health more than low testosterone.	Bodybuilding protocols and selective estrogen suppression trials.	Placebo-controlled trials prove estradiol is essential for male sexual desire, bone mineral density, and visceral fat regulation; severe suppression causes vasomotor instability and sexual dysfunction (Finkelstein et al., 2013).	Level B(Human RCT)	Strong Support

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

Domain	Clinical Action	Dosing / Target	Primary Endpoint
Diagnostic Verification	Perform minimum two separate fasting morning blood draws (between 7:00 AM and 9:00 AM) after ≥8 hours of restful sleep and normocaloric feeding.	Total Testosterone: Confirm < 264–300 ng/dL on both draws (Bhasin et al., 2017).	Elimination of pre-analytical circadian and postprandial false-positive hypogonadism diagnoses.
Assay Methodology	Utilize Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) and Equilibrium Dialysis for androgen profiling.	Free Testosterone: Confirm < 50–65 pg/mL (< 2% bioavailable fraction).	Avoidance of immunoassay cross-reactivity and calculation errors from albumin/SHBG shifts.
Adiposity & Metabolic Management	Implement hypocaloric dietary intervention combined with progressive resistance exercise to reduce visceral fat.	Target waist-to-height ratio < 0.50; achieve 5%–10% total body weight reduction in overweight/obese males.	Normalization of hepatic SHBG synthesis and endogenous testosterone elevation by 100–200+ ng/dL (Marriott et al., 2023).
TRT Cardiovascular Risk Mitigation	Restrict testosterone therapy strictly to confirmed clinical and biochemical hypogonadism; avoid supraphysiological dosing.	Maintain mid-normal trough levels (450–650 ng/dL); monitor hematocrit, keeping < 54% via dose titration (Lincoff et al., 2023).	Prevention of secondary polycythemia, pathological left ventricular hypertrophy, and off-label MACE risk.

Experimental Tier (Level C/D Evidence - High Safety Margin)

Targeted Carbohydrate Refeeding: In lean resistance trainees experiencing low energy availability and elevated SHBG following hypocaloric dieting, implement a 24- to 48-hour carbohydrate refeed (increasing carbohydrate intake to 4.0–6.0 g/kg/day while reducing fat intake). Mechanism: insulin spikes suppress hepatic SHBG transcription and stimulate central leptin signaling, transiently upregulating GnRH and LH pulsatility. Monitor morning resting heart rate and subjective recovery markers.
Urological Varicocele Screening: In resistance-trained men presenting with unexplained secondary hypogonadism (testosterone 200–350 ng/dL) despite optimal body composition and sleep, obtain a scrotal color Doppler ultrasound to evaluate pampiniform plexus reflux during the Valsalva maneuver. If high-grade clinical varicocele is present, surgical or microsurgical repair can yield a 100–150 ng/dL increase in serum testosterone (Gomes et al., 2021).
Sleep Architecture Protection: Enforce a strict minimum sleep target of 7 to 8.5 hours nightly in a thermoregulated room (65°F–68°F). Avoid chronic restriction below 6 hours to prevent hypothalamic-pituitary suppression. Track slow-wave sleep duration and rule out obstructive sleep apnea via home sleep apnea testing (HSAT) if daytime fatigue persists.
Macronutrient Fat Floor Adherence: Ensure that hypocaloric dieting protocols maintain a dietary fat intake of at least 0.6 to 0.8 g/kg/day (or ~20% to 25% of total caloric intake) to preserve steroidogenic substrate availability.Completely eliminating dietary lipids accelerates gonadal suppression.

Produced by Gemini 2.5 Pro

John_Hemming · October 29, 2026, 1:22am

There are clearly cases where people have suffered from high HCT.

I am not sure where the danger point is, but it does seem that there is one.

Is there an overly cautious view. I dont know, but i dont see an argument not to be cautious.

The argument that HCT increases viscosity seems watertight.

chatGPT:

Worked for 3m 59s

I found fatal cases in which raised HCT was considered a contributor, although none establishes that HCT alone caused death.

Case report Documented HCT Fatal outcome and limitations

Santana et al., 2016 — Eisenmenger syndrome 63% during the final admission, previously 67% A 56-year-old man died with extensive pulmonary-artery thrombosis, heart failure and cardiogenic shock, confirmed at autopsy. The authors considered the marked HCT elevation a likely contributor to the extensive thrombosis. He also had severe congenital heart disease and pulmonary hypertension.
Riekki et al., 2019 — Laparoscopic hepatectomy in uncontrolled polycythaemia vera 65% before surgery; 39–56% afterwards A 78-year-old man developed extensive leg DVT and bilateral pulmonary emboli following liver surgery, then died on postoperative day 32 from respiratory complications. The authors describe fatal thrombotic complications, but cancer, surgery, immobility and pneumonia were additional contributors.
Hyder et al., 2020 — Recurrent thrombosis in polycythaemia vera 50% at initial presentation; HCT at death not reported A 64-year-old woman initially presented with pulmonary embolism. Despite subsequent warfarin and intermittent phlebotomy, she developed recurrent thrombosis and a fatal massive pulmonary embolism. She had JAK2-positive polycythaemia vera and a white-cell count of 40,000/µL, so this cannot be attributed to HCT alone. Conference case report.

For testosterone specifically, the most directly relevant fatal account I found is Hematologist Opines on Fatal Testosterone Therapy. It describes a man given ten Testopel pellets who arrived at hospital with HCT above 60%, suffered cardiopulmonary arrest and died. The account says his death certificate attributed death to hyperviscosity from polycythaemia caused by elevated testosterone. However, this is a medico-legal case summary, not a peer-reviewed medical report, and I could not independently verify the death certificate or clinical records.

A peer-reviewed 2025 androgen-use case describes a man with an earlier HCT of 56.9% who later died, probably from pulmonary embolism. His HCT had normalised following treatment, and the authors lacked an official autopsy report. I would therefore not count it as demonstrated death from high HCT.

LukeMV · October 29, 2026, 1:39am

I’m glad you posted this because I would have if you didn’t. Good to hear you coming around on this topic.

Anecdotally, my hematocrit has been in the high 50s for over 10 years. I have no symptoms or any other risk factors with otherwise clean labs. There’s really no solution to my problem besides coming off TRT. If I can get access to Rusfertide, I would give it a shot. I am not concerned about my hematocrit anymore, but I would still like to see the number go down just for peace of mind.

LukeMV · October 29, 2026, 1:43am

I agree with you here. We have been told that high hematocrit is really dangerous based on polycythemia vera patients so it’s easy to pin these deaths on that, but there could have been other things that caused it instead. We just don’t know. You would be surprised how many people have hematocrits in the high 50s or low 60s. I’m not saying it’s a good thing, but the number does fluctuate quite a bit for things like hydration. There is also no evidence that donating blood or phlebotomizing reduces risk, despite the fact doctors are telling their patients to do it all the time, and in turn, depleting their ferritin.